{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:47:38Z","timestamp":1793710058972,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2024.12.264","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T20:41:39Z","timestamp":1736973699000},"page":"286-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-9598","authenticated-orcid":false,"given":"Siamak","family":"Daneshmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.F.","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Sweiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cutie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.12.264_bib0001","unstructured":"Ferlay J., Ervik M., Lam F., et al. Global Cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer. (https:\/\/gco.iarc.who.int\/today). Accessed February 4, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0002","unstructured":"Roser M., Ritcher H. The global disease burden from cancer. (https:\/\/ourworldindata.org\/cancer#the-global-disease-burden-from-cancer). Accessed November 7, 2023."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0003","doi-asserted-by":"crossref","first-page":"273 e1- e9","DOI":"10.1016\/j.urolonc.2022.01.007","article-title":"Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer","volume":"40","author":"Golla","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin in the Veterans Affairs Health system","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0005","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Bladder Cancer V4.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 30, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0006","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0007","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0009","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0010","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1100\/tsw.2011.30","article-title":"Recognition and treatment of BCG failure in bladder cancer","volume":"11","author":"Lightfoot","year":"2011","journal-title":"Sci World J"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0011","unstructured":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). (https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2024.pdf). Accessed May 24, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0012","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170138","article-title":"Defining priorities to improve patient experience in non-muscle invasive bladder cancer","volume":"4","author":"Garg","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0016","article-title":"Utilization and outcomes of radical cystectomy for high-grade non-muscle-invasive bladder cancer in elderly patients","author":"Parker","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0019","first-page":"28","article-title":"Can we lower the rates of cystectomy complications by modifying risk factors? A review of the literature","volume":"75","author":"Hladun","year":"2022","journal-title":"Cent European J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0020","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2023.41.16_suppl.4508","article-title":"SWOG S1011: a phase III surgery trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at the time of radical cystectomy for muscle invasive urothelial cancer","volume":"41","author":"Lerner","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-018-0402-z","article-title":"Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy","volume":"18","author":"Froehner","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0022","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.ejso.2014.10.004","article-title":"Contemporary 90-day mortality rates after radical cystectomy in the elderly","volume":"40","author":"Schiffmann","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0023","doi-asserted-by":"crossref","first-page":"344 e1-e9","DOI":"10.1016\/j.urolonc.2022.02.009","article-title":"The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial","volume":"40","author":"Daneshmand","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0024","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0025","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC) : a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0026","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine) administration in leukemia","volume":"50","author":"Grunewald","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0027","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0028","first-page":"2493","article-title":"Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study","volume":"25","author":"Mattioli","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0029","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American Urological Association-defined intermediate risk non-muscle-invasive bladder cancer patients: a phase 1b study","volume":"62","author":"van Valenberg","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0031","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1464-410X.2010.09496.x","article-title":"Pharmacokinetic study to optimize the intravesical administration of gemcitabine","volume":"106","author":"Gontero","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0032","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0033","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdj970","article-title":"Pharmacokinetic evaluation of gemcitabine and 2\u2032, 2\u2032-difluorodeoxycytidine-5\u2032-triphosphate after prolonged infusion in patients affected by different solid tumors","volume":"17","author":"Cattel","year":"2006","journal-title":"Ann Oncol"},{"issue":"13_suppl","key":"10.1016\/j.urolonc.2024.12.264_bib0034","article-title":"Significant cytotoxic and immunomodulatory effects of continuous low dose intravesical gemcitabine in rodent bladder tumor models","volume":"78","author":"Giesing","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0035","unstructured":"ClinicalTrials.gov. A study of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with non-muscle invasive bladder cancer (NMIBC) unresponsive to intravesical bacillus Calmette-Gu\u00e9rin who are ineligible for or elected not to undergo radical cystectomy (SunRISe-1). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640623). Accessed February 1, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0036","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.115","volume":"32","author":"Van der Heijden","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0037","first-page":"S1254","article-title":"Results from SunRISe-1 in patients with bacillus Calmette\u2013Gu\u00e9rin (BCG) -unresponsive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0038","unstructured":"ClinicalTrials.gov. A study of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive bladder cancer (MIBC) of the bladder (SunRISe-2). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04658862). Accessed February 1, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0039","doi-asserted-by":"crossref","first-page":"TPS4586","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4586","article-title":"A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder","volume":"39","author":"Williams","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int J Urol"},{"issue":"S1224","key":"10.1016\/j.urolonc.2024.12.264_bib0041","article-title":"SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) in patients (pts) with BCG-naive high-risk non\u2013muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0042","unstructured":"ClinicalTrials.gov. A study of TAR-200 in combination with cetrelimab or TAR-200 alone versus intravesical bacillus Calmette-Gu\u00e9rin (BCG) in participants with BCG-naive high-risk non-muscle invasive bladder cancer (SunRISe-3). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05714202). Accessed February 1, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0043","unstructured":"ClinicalTrials.gov. A study of TAR-200 in combination with cetrelimab and cetrelimab alone in participants with muscle-invasive urothelial carcinoma of the bladder (SunRISe-4). (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04919512). Accessed February 1, 2024."},{"key":"10.1016\/j.urolonc.2024.12.264_bib0044","doi-asserted-by":"crossref","first-page":"TPS584","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS584","article-title":"SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy","volume":"41","author":"Psutka","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.264_bib0045","unstructured":"ClinicalTrials.gov. A study of TAR-200 versus intravesical chemotherapy in participants with recurrent high-risk non-muscle invasive bladder cancer (HR-NMIBC) after bacillus Calmette-Gu\u00e9rin (BCG) (SunRISe-5) (https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06211764). Accessed January 30, 2024."},{"issue":"5S_suppl","key":"10.1016\/j.urolonc.2024.12.264_bib0046","first-page":"e987","article-title":"First safety and efficacy results of the TAR-210 erdafitnib intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"211","author":"Vilaseca","year":"2024","journal-title":"J Urol"},{"issue":"5S2_suppl","key":"10.1016\/j.urolonc.2024.12.264_bib0047","first-page":"e11","article-title":"MoonRISe-1: phase 3 study of TAR-210, an erdafitinib intravesical delivery system, versus intravesical chemotherapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer with susceptible FGFR alterations","volume":"211","author":"Li","year":"2024","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:32:01Z","timestamp":1747276321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924010445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143924010445"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.264","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}